SEC Company Response from Imunon, Inc. (IMNN) (CIK 0000749647) (IMNN) — Dec 6, 2017
Imunon, Inc. (IMNN) (CIK 0000749647)
Date: Dec. 6, 2017 · CIK: 0000749647 · Accession: 0001437749-17-020234
AI Filing Summary & Sentiment
File numbers found in text: 333-221543
Show Raw Text
CORRESP 1 filename1.htm clsn20171206_corresp.htm Celsion Corporation 997 Lenox Dr., Suite 100 Lawrenceville, New Jersey 08648 December 6, 2017 VIA EDGAR Division of Corporation Finance Office of Healthcare & Insurance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Irene Paik and Erin Jaskot Re: Celsion Corporation Registration Statement on Form S-1 Filed November 14, 2017 (File No. 333-221543) Dear Ms. Paik and Ms. Jaskot: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Celsion Corporation, a Delaware corporation (the “Registrant”), hereby requests that the effectiveness of the registration statement on Form S-1 (File No. 333-221543), as amended by Pre-Effective Amendment No. 1 and Pre-Effective Amendment No. 2, as filed with the Securities and Exchange Commission on the November 22, 2017 and December 1, 2017, respectively, be accelerated so that the registration statement becomes effective at 4:00 p.m. Eastern Time, on December 8, 2017, or as soon thereafter as practicable. If you have any questions or require any additional information with respect to any of the matters discussed in this letter, please contact Sam Zucker of Sidley Austin LLP, counsel to the Registrant, at (650) 565-7111. Very truly yours, Celsion Corporation By: /s/ Jeffrey W. Church Jeffrey W. Church Senior Vice President and Chief Financial Officer (Principal Financial Officer) cc: Michael H. Tardugno, Chairman of the Board, President and Chief Executive Officer, Celsion Corporation Sam Zucker, Sidley Austin LLP